Invasight

accelerates drug discovery and enables the design of specific protein-protein interaction antagonists (PPIAs) against non-traditional intracellular protein targets, which cause cancer cell invasion

Invasight has raised €4.3M across 1 funding round from 2 investors, most recently a Seed round in Jun 2022. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.